Lineage Cell Therapeutics
LCTX
#8128
Rank
C$0.24 B
Marketcap
$1.30
Share price
1.93%
Change (1 day)
-2.53%
Change (1 year)

P/S ratio for Lineage Cell Therapeutics (LCTX)

P/S ratio as of November 2024 (TTM): 27.9

According to Lineage Cell Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.58. At the end of 2024 the company had a P/S ratio of 30.4.

P/S ratio history for Lineage Cell Therapeutics from 2001 to 2024

PS ratio at the end of each year

Year P/S ratio Change
202430.442.76%
202321.357.65%
202213.5-87.24%
2021106-68.96%
2020342278.58%
201990.210.04%
201882.0-46.14%
2017152-8.1%
201616613.12%
2015146-2.39%
2014150110.2%
201371.4-91.97%
20128881238.34%
201166.4-34.46%
201010136.92%
200974.0164.13%
200828.0210.09%
20079.0375.44%
20065.15-32.86%
20057.67-80.38%
200439.115.37%
200333.9-40.03%
200256.5-83.96%
2001352

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA